Phibro Animal Health beat earnings estimates in all 4 of the last 4 quarters with average surprise of 16.7% and a return on equity of 30%, but carries negative free cash flow at 19% of net income and a debt-to-equity ratio of 2.2 that raises value-trap warning flags alongside the attractive forward price-to-earnings of 9.7x.
Thesis pillars
- Perfect Earnings Beat Streak↑Improving
- Strong Return On Equity→Stable
- Negative Free Cash Flow Red Flag→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Aug 26, 2026· older than 90 days
Phibro Animal Health Corporatio (PAHC) Stock Analysis
Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $39.43, but acceptable to hold if already in. Reasons: Concentration risk — Product: livestock sector; Analyst target reached - limited upside remaining.
Phibro Animal Health makes and sells medicated feed additives (antibacterials and anticoccidials), nutritional specialties, vaccines and trace-mineral nutrition products for poultry, cattle, swine and other livestock, plus specialty ingredients for personal care and industrial... Read more
Hold if already holding. Not a fresh buy at $39.43, but acceptable to hold if already in. Reasons: Concentration risk — Product: livestock sector; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.8/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.
About Phibro Animal Health Corporatio
About Phibro Animal Health Corporatio
Phibro Animal Health reported net sales of $1.5 billion in the fiscal year ended June 30, 2026, up 17% from $1.3 billion, across three segments: Animal Health at $1.2 billion, Mineral Nutrition at $282 million and Performance Products at $74 million. The company markets approximately 790 product lines in approximately 90 countries to approximately 4,800 customers, with the United States contributing 58% of sales and poultry 36% of sales by species.
Animal Health is the profit engine, making up 77% of net sales and 91% of segment Adjusted EBITDA before corporate costs. Within it, medicated feed additives and other products brought in $811 million, nutritional specialties $195 million and vaccines $156 million. Products reach integrated poultry, cattle and swine producers directly or through feed manufacturers, wholesalers, distributors and veterinarians. The Zoetis medicated feed additive portfolio, bought on October 31, 2024 for about $297.5 million with term loan borrowings, contributed $358.2 million of net sales in fiscal 2026 against $208.2 million the year before. Mineral Nutrition sells trace minerals such as zinc, manganese and copper, mainly in North America, with pricing largely based on the cost of underlying commodity metals, while Performance Products supplies specialty ingredients to personal care, industrial chemical and catalyst customers. The company is building a companion animal line, including the Restoris canine dental device launched in October 2025.
Show full overview
Regulation of antibacterials is the lens that matters most. The 10-K states that a material portion of sales and gross profits comes from antibacterials and related products, and lists restrictions on antibacterial use in food-producing animals, including FDA Guidance 273, among its risks. The potential FDA withdrawal of approval for the Mecadox (carbadox) swine product is flagged separately, and a new Brazilian framework may change how virginiamycin is sold and used there. Because the company also cites dependence on its Israeli and Brazilian operations and a substantial level of indebtedness, a regulatory setback in a single market could weigh on both earnings and debt-service capacity.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Phibro Animal Health Corporatio's most recent 10-K filing, extracted October 18, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Phibro Animal Health Corporatio
Latest news
- NEWS Phibro Animal Health Q1 Adj. EPS $0.79 Misses $0.80 Estimate, Sales $386.800M Beat $382.204M Estimate — benzinga Nov 4, 2026 neutral
- NEWS Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy? - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Should Value Investors Buy Phibro Animal Health (PAHC) Stock? - Yahoo Finance — Yahoo Finance Oct 27, 2026 neutral
- NEWS (PAHC) Phibro Animal Health Expects Fiscal 2027 Revenue Range $1.55B - $1.60B, vs. FactSet Est of $1.55B - marketscreene — marketscreener.com Aug 26, 2026 neutral
- NEWS Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars - StockStory — StockStory Aug 26, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:44:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductantibacterials and other related products10-K Item 1A: 'a material portion of our sales and gross profits are generated by antibacterials and other related products'
- HIGHProductlivestock sector10-K Item 1: 'Our business is currently concentrated in the livestock sector.'
- MEDIUMregulatoryFDA approval of Mecadox (carbadox)10-K Item 1A: 'the potential FDA withdrawal of approval of our Mecadox® (carbadox) product'
- MEDIUMGeographicIsraeli and Brazilian operations10-K Item 1A: 'our dependence on our Israeli and Brazilian operations'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $39.43, but acceptable to hold if already in. Reasons: Concentration risk — Product: livestock sector; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Analyst target $39.95 (+1.3%), stop $36.67 (−7.5%), A.R:R 0.2:1. Score 5.8/10, moderate confidence.
Analyst target: $39.95 (+1.3% upside). Analyst target $39.95 (+1.3%), stop $36.67 (−7.5%), A.R:R 0.2:1. Stop-loss: $36.67.
Concentration risk — Product: livestock sector; Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4).
Phibro Animal Health Corporatio trades at a P/E of 16.2 (forward 10.2). TrendMatrix value score: 8.0/10. Verdict: Hold.
9 analysts rate PAHC, with a consensus score of 3.9/5. 3 analysts publish price targets averaging $47.
What does Phibro Animal Health Corporatio do?Phibro Animal Health makes and sells medicated feed additives (antibacterials and anticoccidials), nutritional...
Phibro Animal Health makes and sells medicated feed additives (antibacterials and anticoccidials), nutritional specialties, vaccines and trace-mineral nutrition products for poultry, cattle, swine and other livestock, plus specialty ingredients for personal care and industrial customers. Fiscal 2026 net sales were $1.5 billion, with Animal Health at 77% and the United States at 58%. The October 2024 purchase of Zoetis's feed additive portfolio drove recent growth.